Chimerigen Laboratories - Immune Regulation Proteins

The Experts for High Quality Fusion Proteins

Since many years Chimerigen Laboratories, LLC (Chimerigen) develops, manufactures and markets high quality and leading edge proteins for biomedical and immunology research. One of Chimerigen's specialty is the production of unique immunoglobulin based chimeric fusion proteins using advanced cellular and molecular biological techniques. These reagents are used successfully in basic and applied research, providing advanced Immune Checkpoint Proteins, Interleukins and other Cytokines. AdipoGen has now become a trusted and reliable marketing and sales partner for Chimerigen's product panel. Because of the high performance characteristics and quality the Chimerigen fusion proteins are widely recognized reagents and are cited in many scientific publications.

Non-lytic Ig-based Chimeric Fusion Cytokines with Long Circulating Half-life

The potential clinical application of cytokines to modulate immune responses is very high. Unfortunately, most cytokines have short circulating half-lives. Therefore, to facilitate the study of cytokine effects in vivo, a variety of non-lytic immunoglobulin-based chimeric cytokine fusion proteins have been created, in which a cytokine sequence had been genetically fused to the hinge, CH2 and CH3 regions of an immunoglobulin.

These non-lytic fusion proteins possess both the biological functions of the cytokine moiety and a prolonged circulating half-life determined by the Fc domain. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC). These fusion molecules also have the promise of being minimally to negligibly immunogenic since they are made entirely from elements derived from the species to be treated.

Structure of Fusion Proteins

Figure: General structure of mouse non-lytic fusion proteins.

Literature:
- Localization of the binding site for the human high-affinity Fc receptor on IgG: A.R. Duncan, et al.; Nature 332, 563 (1988)
- The binding site for Clq on IgG: A.R. Duncan & G. Winter; Nature 332, 738 (1988)
- Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation: X.X. Zheng, et al.; J. Immunol. 154, 5590 (1995)

Chimerigen Laboratories, LLC and Adipogen Life Sciences, Inc. provide all Chimerigen Products worldwide. Please contact us for more information.

For Product Inquiries: info@chimerigen.ch

Latest Insights: IL-35 & its Involvment in Type 1 Diabetes (T1D)

Singh, et al. 2015, using Chimerigen's IL-35 (mouse):Fc (human) (rec.) (CHI-MF-11135) as a key reagent, recently showed that circulating IL-35 levels were decreased in human Type 1 Diabetes (T1D) patients compared to healthy controls. The findings of this study suggest that insufficient IL-35 levels play a pivotal role in the development of T1D and that treatment with IL-35 should be investigated in treatment of T1D and other autoimmune diseases.

LIT: Interleukin-35 administration counteracts established murine type 1 diabetes – possible involvement of regulatory T cells: K. Singh, et al.; Sci. Rep. 5, ID12633 (2015) - Link to Publication

PID	Product Name	Size	Source	Purity	Endotoxin
CHI-MF-11135	IL-35 (mouse):Fc (human) (rec.)	5 µg	CHO cells	≥98%	<0.06EU/μg

Selected High Quality Fusion Proteins from Chimerigen

Fc Fusion Proteins Highlights

PID	Product Name	Size	Source	Purity	Endotoxin
CHI-HF-210A4	CD152 [CTLA-4] (human):Fc (human) (rec.)	100 µg 500 µg 1 mg	NS1 cells	≥98%	<0.06EU/μg
CHI-MF-110A4	CD152 [CTLA-4] (mouse):Fc (mouse) (rec.)	100 µg 500 µg 1 mg	NS1 cells	≥98%	<0.06EU/μg
CHI-HF-21002	IL-2 (human):Fc (human) (rec.) MultiPack	50 µg 3 x 50 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-21006	IL-6 (human):Fc (human) (rec.) MultiPack	50 µg 3 x 50 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-21015M	IL-15 (mutant) (human):Fc (human) (rec.)	50 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-21115MBI	IL-15 (mutant) (human):Fc (mouse) (rec.) (Biotin)	1 Vial	CHO cells	≥98%	<0.06EU/μg
CHI-HF-210T1	Tim-1 (human):Fc (human) (rec.)	100 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-210T3	Tim-3 (human):Fc (human) (rec.)	100 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-210T4	Tim-4 (human):Fc (human) (rec.)	100 µg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-210TGFBM	TGFß1 (mutant) (human):Fc (human) (rec.)	100 µg	CHO cells	≥98%	<0.06EU/μg

Non-lytic Fc Fusion Proteins Highlights

PID	Product Name	Size	Source	Purity	Endotoxin
CHI-MF-120A4	CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) (non-lytic)	100 µg 500 µg 1 mg	NS1 cells	≥98%	<0.06EU/μg
CHI-HF-22002	IL-2 (human):Fc (human) (rec.) (non-lytic) MultiPack	50 μg 3 x 50 μg	NS1 cells	≥98%	<0.06EU/μg
CHI-MF-12002	IL-2 (mouse):Fc (mouse) (rec.) (non-lytic) MultiPack	10 μg 5 x 10 μg	NS1 cells	≥98%	<0.06EU/μg
CHI-HF-22004	IL-4 (human):Fc (human) (rec.) (non-lytic) MultiPack	10 μg 5 x 10 μg	NS1 cells	≥98%	<0.06EU/μg
CHI-MF-12004	IL-4 (mouse):Fc (mouse) (rec.) (non-lytic) MultiPack	10 μg 5 x 10 μg	NS1 cells	≥98%	<0.06EU/μg
CHI-HF-22006	IL-6 (human):Fc (human) (rec.) (non-lytic) MultiPack	50 μg 3 x 50 μg	CHO cells	≥98%	<0.06EU/μg
CHI-MF-12006	IL-6 (mouse):Fc (mouse) (rec.) (non-lytic) MultiPack	50 μg 3 x 50 μg	CHO cells	≥98%	<0.06EU/μg
CHI-HF-22010	IL-10 (human):Fc (human) (rec.) (non-lytic) MultiPack	10 μg 5 x 10 μg	NS1 cells	≥98%	<0.06EU/μg
CHI-MF-12010	IL-10 (mouse):Fc (mouse) (rec.) (non-lytic) MultiPack	10 μg 5 x 10 μg	NS1 cells	≥98%	<0.06EU/μg

Visit our website for a COMPLETE PRODUCT OVERVIEW.

More Information		Product Flyer
Please contact us at info@chimerigen.ch to receive a print copy of the Chimerigen Immune Regulation Proteins Brochure 2016! Also available for download!		Download